A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions

Solid Tumor, Adult

Interventions

DRUG

BY101298 Capsules

An oral DNA-PK Inhibitor

Trial Locations (1)

Cancer Hospital Affiliated to Shandong First Medical University / Shandong Cancer Research Institute / Shandong Cancer Hospital, Jinan